CLOs on the Move

MiMedx

www.mimedx.com

 
MiMedx is a biopharmaceutical company developing, manufacturing and marketing regenerative biologics utilizing human placental allografts for multiple sectors of healthcare. “Innovations in Regenerative Medicine” is the framework behind our mission to provide physicians with products and tissues to help the body heal itself. We process human placental tissue utilizing our proprietary PURION® process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization. Since our founding, research and development has been the cornerstone of our organization. As a result, we have grown to be the leader in placental based products ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.mimedx.com
  • 1775 West Oak Commons CT. NorthEast
    Marietta, GA USA 30062
  • Phone: 770.651.9100

Executives

Name Title Contact Details
Ronald Strauss
 Associate Vice President-Compliance Profile
Guilhem Denozi�re
 Associate Vice President, Global Regulatory Affairs Profile
David Emch
 Vice-President, Senior Counsel Profile
William Butch Hulse
 General Counsel Profile
William Hulse
 General Counsel and Secretary Profile

Similar Companies

Bio Essence Corp

Bio Essence Corp is a Richmond, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Radix Biosolutions

Radix Biosolutions is a Georgetown, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Deepcell

Our mission is to enable novel biological insights at the single-cell level for improved diagnosis and treatment of disease.

Armata Pharmaceuticals

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.

SeLux Diagnostics

SeLux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic.